1. Healio
  2. Hematology/Oncology
  3. Learn Immuno-Oncology
  4. Immunotherapy: Adverse Events
Your Module Progress 
Immunotherapy: Adverse Events
Immunotherapy: Adverse Events
  • 1. Immunotherapy must be discontinued in all patients who experience irAEs, regardless of grade.
  • Your Colleagues Responded
  • 0%
  • 0%
  • 2. This classification of irAEs is the most common and often has the earliest onset of symptoms.
  • Your Colleagues Responded
  • 0%
  • 0%
  • 0%
  • 0%
  • 3. Patients report higher incidence of ______________ with anti-CTLA therapy compared with ____________ that is more often associated with anti-PD-1/L1 therapy.
  • Your Colleagues Responded
  • 0%
  • 0%
  • 0%
  • 0%
  • 4. Saliva substitutes and/or artificial tears are often used in the treatment of _______________ a rheumatologic irAE.
  • Your Colleagues Responded
  • 0%
  • 0%
  • 0%
  • 0%
  • 5. ICI therapy can affect the heart in both _____________ and ___________ manner.
  • Your Colleagues Responded
  • 0%
  • 0%
  • 0%
  • 0%
  • 6. Most patients receiving immunotherapy only experience a single irAE during their treatment course.
  • Your Colleagues Responded
  • 0%
  • 0%
 Previous Section Continue  Next Module 
Expert Perspectives